AtriCure and Axonics reported procedure volume rebounds and both firms increased their 2022 forecasts. Still, the shares of the companies dropped late last week
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,